Ketamine Clinical Trials
Evaluation of Schemes of Administration of Intravenous Ketamine in Treatment-resistant Depression: Clinical-neuroimaging Correlation
To see complete record on clinicaltrials.gov, please visit this link
Organisation Name: National Institute of Neurology and Neurosurgery, Mexico
Overal Status: Unknown status
Start Date: October 1, 2018
Last Update: September 10, 2019
Lead Sponsor: National Institute of Neurology and Neurosurgery, Mexico
Brief Summary: Mexico, prevalence reported for major depressive disorder (MDD) is of 7.2%. It is currently in the top 5 causes of disability worldwide. One third of patients will not achieve remission after two treatments, being classified as treatment-resistant. In a neurochemical level, evidence shows dysregulation of the excitatory neurotransmitter Glutamate in patients with MDD. Chronic stress has been related to this dysregulation. Ketamine, has shown to regulate glutamatergic neurotransmission, and specially promote the release and production of neurotrophic factors key in the causes of MDD inhibited by glutamate dysregulation), and allow restoration of areas affected.Conditions
Clinical studies of ketamine in MDD have shown robust, durable , and rapid effects (during the first 4-24 hours), allowing a great opportunity for patients who do not achieve benefits from antidepressants or patients with suicidal ideation . These results have been reported in metaanalysis.
To our knowledge, there are no studies using Magnetic Resonance Spectroscopy, in areas related to MDD, after a series of ketamine administrations, which we think may show changes after this chronic administration and explain its antidepressant properties.
Goals: Provide clinical evidence of responseas well as a neurological basis or biomarker of response to a series of ketamine infusions.
- Treatment Resistant Depression
Total execution time in seconds: 0.21833801269531